Phase I dose-escalating trial of hepcidin [LJPC-401] in patients at risk of iron overload

Trial Profile

Phase I dose-escalating trial of hepcidin [LJPC-401] in patients at risk of iron overload

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Hepcidin (Primary)
  • Indications Iron overload
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 07 Sep 2016 Results published in La Jolla media release.
    • 08 Aug 2016 According to La Jolla media release, company plan to report results in September 2016
    • 06 May 2016 According to a La Jolla Pharmaceutical media release, complete results from this trial are expected in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top